Medicortex International (MEDFIN) Q2 2026 earnings summary

Executive summary

• Completed an acquisition of 89.9% of Medicortex Finland Oyj, resulting in a new consolidated group as of June 29, 2026.

• Company rebranded and began trading under the new ticker MEDFIN B from July 1, 2026.

• Strategic focus on commercializing the ProbTBI® diagnostic test for traumatic brain injury, with GMP manufacturing and multicenter clinical studies underway.

Financial highlights

• Group net sales for Q2 2026 were 0 TKR; parent company net sales were 57 TKR, down 4% year-over-year.

• Group operating profit for Q2 was 9,734 TKR, driven by a one-time non-cash income of 11,472 TKR (negative goodwill from the acquisition).

• Excluding the one-time item, group net result for Q2 was -1,890 TKR.

• Parent company Q2 net result was -3,299 TKR; group Q2 net result attributable to shareholders was 9,582 TKR.

• Cash flow from operations for Q2 was -308 TKR for the group and -1,477 TKR for the parent.

Outlook and guidance

• Focus on advancing ProbTBI® to regulatory approval and market launch, with ongoing clinical validation and manufacturing scale-up.

• Legacy investment holdings are being divested as the group transitions to a pure medtech focus.